Recombinant monoclonal antibodies (mAbs) are one of today's most successful therapeutic
classes in inflammatory diseases and oncology. A wider accessibility and implementation …

The emergence of West Nile virus (WNV) in North America in 1999 as a cause of severe
neurological disease in humans, horses and birds stimulated development of vaccines for …

The key to an effective HIV vaccine is development of an immunogen that elicits persisting
antibodies with broad neutralizing activity against field strains of the virus. Unfortunately …

Broadly neutralizing antibodies (bNAbs) are being explored for HIV-1 prevention and cure
strategies. However, administration of purified bNAbs poses challenges in resource-poor …

Monoclonal antibodies are successfully used in the clinic. However, repeated high-dose
bolus injections imply high costs. As an alternative to recombinant protein administration …

The disease progression with West Nile virus (WNV) infection in humans leads to meningitis
or encephalitis and may cause death, particularly among elderly and immunocompromised …

Abstract Direct attenuation of West Nile (WN) virus strain NY99 for the purpose of vaccine
development is not feasible due to its high virulence and pathogenicity. Instead, we created …

For the development of a human West Nile (WN) infectious DNA (iDNA) vaccine, we created
highly attenuated chimeric virus W1806 with the serological identity of highly virulent WN …

Purified proteins such as antibodies are widely used as therapeutic agents in clinical
medicine. However, clinical-grade proteins for therapeutic use require sophisticated …

The use of antibodies as a treatment for disease has it origins in experiments performed in
the 1890s, and since these initial experiments, monoclonal antibodies (mAbs) have become …